Promising research is being conducted on targets such as Flt3L and IL-24 in the treatment of PCa, but additional verification is necessitated to confirm their therapeutic efficacy.[51,52] Consequently, exploring the interaction mechanisms between different inflammatory cytokines and their impact on triggering immune responses are crucial for researching the etiology and prognosis of PCa. This evidence concerns the gene IL24 and posterior cortical atrophy.